CCNL2

Summary

CCNL2 (cyclin L2, HGNC:20570) is a protein-coding gene on chromosome 1p36.33, encoding Cyclin-L2 (Q96S94). Regulatory component of the cyclin-L-CDK11 complex that regulates transcription and pre-mRNA splicing.

The protein encoded by this gene belongs to the cyclin family. Through its interaction with several proteins, such as RNA polymerase II, splicing factors, and cyclin-dependent kinases, this protein functions as a regulator of the pre-mRNA splicing process, as well as in inducing apoptosis by modulating the expression of apoptotic and antiapoptotic proteins. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Source: NCBI Gene 81669 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 121 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_030937

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20570
Approved symbol	CCNL2
Name	cyclin L2
Location	1p36.33
Locus type	gene with protein product
Status	Approved
Aliases	ania-6b, PCEE, SB138, HLA-ISO, CCNS
Ensembl gene	ENSG00000221978
Ensembl biotype	protein_coding
OMIM	613482
Entrez	81669

Gene structure

Transcript identifiers

Ensembl transcripts: 28 — 12 protein_coding, 9 retained_intron, 4 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined

ENST00000400809, ENST00000408918, ENST00000418865, ENST00000425598, ENST00000463260, ENST00000463895, ENST00000469113, ENST00000471930, ENST00000473872, ENST00000480479, ENST00000480646, ENST00000481223, ENST00000482365, ENST00000482621, ENST00000488340, ENST00000492998, ENST00000496007, ENST00000497013, ENST00000505849, ENST00000858595, ENST00000858596, ENST00000858597, ENST00000858598, ENST00000858599, ENST00000934645, ENST00000934646, ENST00000934647, ENST00000941190

RefSeq mRNA: 8 — MANE Select: NM_030937 NM_001039577, NM_001320153, NM_001320155, NM_001350497, NM_001350498, NM_001350499, NM_001350500, NM_030937

CCDS: CCDS30557, CCDS30558

Canonical transcript exons

ENST00000400809 — 11 exons

Exon	Start	End
ENSE00001589041	1399019	1399335
ENSE00003459548	1390459	1390563
ENSE00003481685	1390230	1390371
ENSE00003490441	1387954	1388065
ENSE00003497083	1398597	1398671
ENSE00003503679	1387777	1387869
ENSE00003539724	1385711	1387582
ENSE00003578981	1390766	1390865
ENSE00003583101	1393396	1393460
ENSE00003636572	1395394	1395514
ENSE00003666121	1398233	1398342

Expression profiles

Bgee: expression breadth ubiquitous, 271 present calls, max score 99.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.6649 / max 246.0578, expressed in 1816 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
9779	28.2480	1816
9777	0.2226	99
9778	0.1943	99

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	99.39	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.28	gold quality
cerebellar hemisphere	UBERON:0002245	99.27	gold quality
right ovary	UBERON:0002118	99.26	gold quality
left ovary	UBERON:0002119	99.24	gold quality
cerebellar cortex	UBERON:0002129	99.23	gold quality
body of uterus	UBERON:0009853	99.22	gold quality
endocervix	UBERON:0000458	99.16	gold quality
left lobe of thyroid gland	UBERON:0001120	99.15	gold quality
right lobe of thyroid gland	UBERON:0001119	99.13	gold quality
metanephros cortex	UBERON:0010533	99.11	gold quality
mucosa of stomach	UBERON:0001199	99.07	gold quality
left uterine tube	UBERON:0001303	99.05	gold quality
adenohypophysis	UBERON:0002196	99.03	gold quality
small intestine Peyer’s patch	UBERON:0003454	98.93	gold quality
ectocervix	UBERON:0012249	98.93	gold quality
tibial nerve	UBERON:0001323	98.92	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.91	gold quality
lower esophagus	UBERON:0013473	98.90	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.90	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.90	gold quality
body of pancreas	UBERON:0001150	98.89	gold quality
minor salivary gland	UBERON:0001830	98.83	gold quality
right lung	UBERON:0002167	98.83	gold quality
skin of abdomen	UBERON:0001416	98.82	gold quality
left adrenal gland cortex	UBERON:0035825	98.82	gold quality
body of stomach	UBERON:0001161	98.81	gold quality
right adrenal gland	UBERON:0001233	98.79	gold quality
right adrenal gland cortex	UBERON:0035827	98.79	gold quality
pituitary gland	UBERON:0000007	98.72	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-10137	no	425.82
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting CCNL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-182-3P	99.57	67.57	825
HSA-MIR-4753-5P	99.54	68.51	1356
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-584-3P	99.35	67.69	1082
HSA-MIR-4279	99.19	66.70	2437
HSA-MIR-4801	98.96	69.42	2096
HSA-MIR-4731-3P	98.56	68.60	1860
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-6735-5P	98.24	65.36	1488
HSA-MIR-4717-5P	98.19	67.97	894
HSA-MIR-7843-5P	98.12	65.26	1421
HSA-MIR-4632-5P	97.82	65.38	1470
HSA-MIR-6879-5P	97.77	65.52	1521

Literature-anchored findings (GeneRIF, showing 8)

• characterize cyclin L2 as a highly mobile component of nuclear speckles and suggest that DYRK1A may regulate splicing by phosphorylation of cyclin L2 (PMID:14623875)
• Data show that a green fluorescent protein (GFP) fusion protein of cyclin L1, in contrast to cyclin L2, was not mobile within the nucleus of living COS7 cells. (PMID:17494991)
• CDK11(p110) interacts physically and functionally with cyclin Lalpha and -beta isoforms and SR proteins to regulate splicing. (PMID:18216018)
• CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. (PMID:24218572)
• Therefore, cyclin L2-mediated control of SAMHD1 levels in macrophages supports HIV-1 replication. (PMID:25532805)
• The Dual-Specificity Kinase DYRK1A Modulates the Levels of Cyclin L2 To Control HIV Replication in Macrophages. (PMID:31852782)
• CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer. (PMID:33849617)
• Exosome miR-23a-3p from Osteoblast Alleviates Spinal Cord Ischemia/Reperfusion Injury by Down-Regulating KLF3-Activated CCNL2 Transcription. (PMID:34937039)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ccnl2	ENSMUSG00000029068
rattus_norvegicus	Ccnl2	ENSRNOG00000018691
drosophila_melanogaster	CycH	FBGN0022936
drosophila_melanogaster	CycT	FBGN0025455
caenorhabditis_elegans		WBGENE00000507
caenorhabditis_elegans		WBGENE00000508
caenorhabditis_elegans		WBGENE00021714

Paralogs (6): CCNT2 (ENSG00000082258), CCNK (ENSG00000090061), CCNT1 (ENSG00000129315), CCNH (ENSG00000134480), CCNL1 (ENSG00000163660), CCNQ (ENSG00000262919)

Protein

Protein identifiers

Cyclin-L2 — Q96S94 (reviewed: Q96S94)

Alternative names: Paneth cell-enhanced expression protein

All UniProt accessions (4): Q96S94, C9J148, J3KRL1, J3QSH2

UniProt curated annotations — full annotation on UniProt →

Function. Regulatory component of the cyclin-L-CDK11 complex that regulates transcription and pre-mRNA splicing. May induce cell death, possibly by acting on the transcription and RNA processing of apoptosis-related factors.

Subunit / interactions. Interacts with the CDK11 (CDK11A or CDK11B) protein kinase to form a serine/threonine kinase holoenzyme complex. Interacts with SAP30BP; promoting assenbly of the cyclin-L-CDK11 cyclin-dependent protein kinase complex. Interacts with POLR2A, the hyperphosphorylated C-terminal domain (CTD) of RNA polymerase II. May form a ternary complex with CDK11B and casein kinase II (CKII). Interacts with pre-mRNA-splicing factors SRSF1, SRSF2 and SRSF7/SLU7.

Subcellular location. Nucleus speckle. Nucleus. Nucleoplasm.

Tissue specificity. Widely expressed.

Domain organisation. Contains a RS region (arginine-serine dipeptide repeat) within the C-terminal domain which is the hallmark of the SR family of splicing factors. This region probably plays a role in protein-protein interactions.

Similarity. Belongs to the cyclin family. Cyclin L subfamily.

Isoforms (5)

UniProt ID	Names	Canonical?
Q96S94-1	1, cyclin L2alpha	yes
Q96S94-2	2, CCNL2s
Q96S94-3	3
Q96S94-4	4, cyclin L2betaB
Q96S94-5	5, cyclin L2betaA

RefSeq proteins (8): NP_001034666, NP_001307082, NP_001307084, NP_001337426, NP_001337427, NP_001337428, NP_001337429, NP_112199* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004367	Cyclin_C-dom	Domain
IPR006671	Cyclin_N	Domain
IPR013763	Cyclin-like_dom	Domain
IPR036915	Cyclin-like_sf	Homologous_superfamily
IPR043198	Cyclin/Ssn8	Family

Pfam: PF00134, PF21797

UniProt features (28 total): compositionally biased region 7, splice variant 7, modified residue 6, region of interest 4, sequence conflict 2, initiator methionine 1, chain 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
9QKZ	ELECTRON MICROSCOPY	2.3
9QKT	ELECTRON MICROSCOPY	2.4
9QL1	ELECTRON MICROSCOPY	2.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96S94-F1	70.06	0.46

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 2, 330, 338, 348, 351, 369

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 176 (showing top): MYOGENIN_Q6, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, KYNG_DNA_DAMAGE_DN, MARTINEZ_RB1_TARGETS_UP, KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_GAMMA_IN_WS, MYOD_01, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_CENTROSOME_CYCLE, GOBP_RNA_SPLICING, MYOD_Q6, KYNG_ENVIRONMENTAL_STRESS_RESPONSE_UP, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME

GO Biological Process (5): regulation of transcription by RNA polymerase II (GO:0006357), regulation of apoptotic process (GO:0042981), regulation of RNA splicing (GO:0043484), regulation of centrosome cycle (GO:0046605), regulation of cell cycle (GO:0051726)

GO Molecular Function (2): cyclin-dependent protein serine/threonine kinase regulator activity (GO:0016538), protein binding (GO:0005515)

GO Cellular Component (4): cyclin-dependent protein kinase holoenzyme complex (GO:0000307), nucleus (GO:0005634), nucleoplasm (GO:0005654), nuclear speck (GO:0016607)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
apoptotic process	1
regulation of programmed cell death	1
RNA splicing	1
regulation of gene expression	1
regulation of primary metabolic process	1
centrosome cycle	1
regulation of cell cycle process	1
regulation of microtubule-based process	1
regulation of cellular component organization	1
cell cycle	1
regulation of cellular process	1
cyclin-dependent protein serine/threonine kinase activity	1
cyclin-dependent protein kinase regulator activity	1
binding	1
serine/threonine protein kinase complex	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

3148 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCNL2	CDK4	P11802	999
CCNL2	CDK6	Q00534	999
CCNL2	CDK2	P24941	999
CCNL2	CDK1	P06493	999
CCNL2	CDKN1A	P38936	996
CCNL2	CDKN1B	P46527	995
CCNL2	CDK9	P50750	994
CCNL2	CDKN2A	P42771	962
CCNL2	CCNA2	P20248	958
CCNL2	CCND1	P24385	950
CCNL2	CCNA1	P78396	950
CCNL2	CDK5	Q00535	933
CCNL2	CCNB1	P14635	909
CCNL2	CCND3	P30281	909
CCNL2	CDK3	Q00526	903

IntAct

53 interactions, top by confidence:

A	B	Type	Score
CLOCK	BMAL1	psi-mi:“MI:0914”(association)	0.880
CSNK2A1	EIF3J	psi-mi:“MI:0914”(association)	0.810
GATAD2A	CDK2AP1	psi-mi:“MI:0914”(association)	0.730
KIFAP3	KIF3C	psi-mi:“MI:0914”(association)	0.640
CSNK2A2	PES1	psi-mi:“MI:0914”(association)	0.640
CCNL2	RUNDC3A	psi-mi:“MI:0915”(physical association)	0.560
RUNDC3A	CCNL2	psi-mi:“MI:0915”(physical association)	0.560
CCNL2	ZBTB43	psi-mi:“MI:0914”(association)	0.530
LRRTM4	AP3B1	psi-mi:“MI:0914”(association)	0.530
CDK11A	HSP90AA1	psi-mi:“MI:0914”(association)	0.530
ZCRB1	RPSA	psi-mi:“MI:0914”(association)	0.530
DHX40	TRIM27	psi-mi:“MI:0914”(association)	0.530
CCNL2	TUFM	psi-mi:“MI:0915”(physical association)	0.400
CCNL2		psi-mi:“MI:0915”(physical association)	0.370
Racgap1	DDX3X	psi-mi:“MI:0914”(association)	0.350
Oxnad1	KPNA6	psi-mi:“MI:0914”(association)	0.350
Bcas2	PEX10	psi-mi:“MI:0914”(association)	0.350
HDAC1	TRAK1	psi-mi:“MI:0914”(association)	0.350
JAK3	WDR46	psi-mi:“MI:0914”(association)	0.350
KIF22	PSEN2	psi-mi:“MI:0914”(association)	0.350
CBR3	LDLR	psi-mi:“MI:0914”(association)	0.350
CENPQ	CENPX	psi-mi:“MI:0914”(association)	0.350
JMJD6	U2SURP	psi-mi:“MI:0914”(association)	0.350
CDK11A	HSP90AA1	psi-mi:“MI:0914”(association)	0.350
CSNK2A2	CNOT1	psi-mi:“MI:0914”(association)	0.350
CSNK2A1	EIF3F	psi-mi:“MI:0914”(association)	0.350
CSNK2B	OSBPL8	psi-mi:“MI:0914”(association)	0.350
RNPS1	C1orf226	psi-mi:“MI:0914”(association)	0.350

BioGRID (139): CCNL2 (Two-hybrid), SMPDL3B (Affinity Capture-MS), GNAZ (Affinity Capture-MS), GNA11 (Affinity Capture-MS), GNAQ (Affinity Capture-MS), PTPRG (Affinity Capture-MS), AP1B1 (Affinity Capture-MS), FYN (Affinity Capture-MS), YES1 (Affinity Capture-MS), LYN (Affinity Capture-MS), SRC (Affinity Capture-MS), ABCF2 (Affinity Capture-MS), PYGB (Affinity Capture-MS), IRF2BP2 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS)

ESM2 similar proteins: A7DTF0, A8X0L9, C8VBH4, G5EBX3, O94446, P0CP02, P0CP03, P14785, P34424, P34425, P34442, P34638, P54816, Q06698, Q19336, Q20318, Q21209, Q22712, Q23243, Q23356, Q23357, Q23541, Q2UMQ5, Q2UTN6, Q4IB50, Q4IEV4, Q4P3S3, Q4WHG1, Q52KE7, Q5A7Q2, Q5ASA5, Q5BKF8, Q5I0H5, Q5ZJP9, Q61T02, Q6AW06, Q6BU95, Q6C710, Q6GN15, Q7RZU4

Diamond homologs: A3LPX1, F1QMB9, O60563, O60583, O74627, O75909, O88874, O96433, P24863, P47821, P55168, Q0E474, Q28F72, Q2QQS5, Q2RAC5, Q3ZCK5, Q4KLA0, Q52KE7, Q56YF8, Q5I0H5, Q5RD50, Q5ZJP9, Q62447, Q6GN15, Q6T8E9, Q6Z7H3, Q7TQK0, Q7ZVX0, Q8GYM6, Q8HXN7, Q8RWV3, Q96S94, Q9AS36, Q9C8P7, Q9FKE6, Q9JJA7, Q9QWV9, Q9R1Q2, Q9UK58, Q9XT26

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
DYRK1A	unknown	CCNL2	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 74 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of PTEN stability and activity	5	16.2×	2e-03
Potential therapeutics for SARS	5	10.0×	6e-03
mRNA Splicing	5	9.6×	7e-03
Metabolism of RNA	8	5.8×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
RNA splicing	6	7.8×	1e-02

Disease & clinical

Clinical variants and AI predictions

ClinVar

121 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	97
Likely benign	9
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2338 predictions. Top by Δscore:

Variant	Effect	Δscore
1:1387583:C:CC	acceptor_gain	1.0000
1:1387775:ACCT:A	donor_gain	1.0000
1:1387776:CCT:C	donor_gain	1.0000
1:1387776:CCTC:C	donor_gain	1.0000
1:1387778:T:TA	donor_gain	1.0000
1:1387865:GCAAG:G	acceptor_gain	1.0000
1:1387866:CAAG:C	acceptor_gain	1.0000
1:1387866:CAAGC:C	acceptor_gain	1.0000
1:1387867:AAG:A	acceptor_gain	1.0000
1:1387868:AG:A	acceptor_gain	1.0000
1:1387869:GC:G	acceptor_loss	1.0000
1:1387870:C:CC	acceptor_gain	1.0000
1:1387872:G:C	acceptor_gain	1.0000
1:1387877:C:CT	acceptor_gain	1.0000
1:1387949:CCTA:C	donor_loss	1.0000
1:1387950:CTAC:C	donor_loss	1.0000
1:1387951:TA:T	donor_loss	1.0000
1:1387952:A:AC	donor_gain	1.0000
1:1387952:AC:A	donor_gain	1.0000
1:1387953:C:A	donor_gain	1.0000
1:1387953:C:CC	donor_gain	1.0000
1:1387953:CCCGT:C	donor_gain	1.0000
1:1388061:TTCCA:T	acceptor_gain	1.0000
1:1388062:TCCA:T	acceptor_gain	1.0000
1:1388063:CCA:C	acceptor_gain	1.0000
1:1388063:CCAC:C	acceptor_gain	1.0000
1:1388064:C:T	acceptor_gain	1.0000
1:1388064:CA:C	acceptor_gain	1.0000
1:1388064:CAC:C	acceptor_gain	1.0000
1:1388066:C:CC	acceptor_gain	1.0000

AlphaMissense

3354 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:1390539:A:G	W262R	1.000
1:1390539:A:T	W262R	1.000
1:1390793:G:C	C244W	1.000
1:1390794:C:T	C244Y	1.000
1:1390803:G:T	A241D	1.000
1:1390847:G:C	S226R	1.000
1:1390847:G:T	S226R	1.000
1:1390849:T:G	S226R	1.000
1:1390853:G:C	N224K	1.000
1:1390853:G:T	N224K	1.000
1:1393397:A:G	W220R	1.000
1:1393397:A:T	W220R	1.000
1:1395399:G:C	H197D	1.000
1:1395401:G:T	P196H	1.000
1:1395416:A:T	V191D	1.000
1:1395421:G:C	F189L	1.000
1:1395421:G:T	F189L	1.000
1:1395422:A:C	F189C	1.000
1:1395422:A:G	F189S	1.000
1:1395423:A:C	F189V	1.000
1:1395423:A:G	F189L	1.000
1:1395423:A:T	F189I	1.000
1:1395437:A:G	L184P	1.000
1:1395437:A:T	L184H	1.000
1:1395445:T:A	R181S	1.000
1:1395445:T:G	R181S	1.000
1:1395449:T:A	E180V	1.000
1:1395469:C:A	K173N	1.000
1:1395469:C:G	K173N	1.000
1:1398307:C:A	K133N	1.000

dbSNP variants (sampled 300 via entrez): RS1000027876 (1:1395842 T>C), RS1000308546 (1:1392445 G>A,C), RS1000334281 (1:1397605 T>C), RS1000366882 (1:1397805 T>C), RS1000553473 (1:1391478 C>T), RS1000646688 (1:1391224 T>C), RS1000716129 (1:1396895 C>A), RS1000781317 (1:1400500 C>G,T), RS1000856398 (1:1400658 A>C), RS1000942243 (1:1386143 T>TG), RS1001084839 (1:1396494 G>A), RS1001191484 (1:1399749 C>A,T), RS1001771090 (1:1389141 G>A,C), RS1002003830 (1:1393608 G>A), RS1002028434 (1:1385590 C>T)

Disease associations

OMIM: gene MIM:613482 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST004131_103	Inflammatory bowel disease	2.000000e-07
GCST004133_40	Ulcerative colitis	3.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL5483186 (PROTEIN COMPLEX), CHEMBL5483187 (PROTEIN COMPLEX), CHEMBL5483188 (PROTEIN COMPLEX), CHEMBL6067576 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.80	Kd	16	nM	MOLIBRESIB
7.30	IC50	50	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 7 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179186: Binding affinity against CCNL2 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.0160	uM

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression, affects binding, increases reaction, decreases expression (+1 more)	5
bisphenol A	decreases methylation, affects expression, affects cotreatment	2
Arsenic	affects cotreatment, decreases expression, increases abundance, increases expression	2
Valproic Acid	affects expression, decreases expression	2
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	increases expression	1
FR900359	increases phosphorylation	1
bisphenol F	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
lead acetate	decreases expression	1
butyraldehyde	decreases expression	1
aflatoxin B2	decreases methylation	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
NSC 689534	affects binding, increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Copper	affects binding, increases expression	1
Dexamethasone	decreases expression, affects cotreatment	1
Endosulfan	decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Lipopolysaccharides	affects expression, affects reaction	1
Phthalic Acids	increases methylation	1
Plant Extracts	affects expression, affects reaction	1
Polychlorinated Biphenyls	affects expression	1
Smoke	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Zidovudine	affects cotreatment, increases expression	1

ChEMBL screening assays

19 unique, capped per target: 19 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5469150	Binding	Selectivity interaction (NanoBRET assay in HEK293T cells) EUB0000121b CDK10	Selectivity Literature for EUbOPEN Chemogenomic Library

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2TP	Abcam HEK293T CCNL2 KO	Transformed cell line	Female
CVCL_SH45	HAP1 CCNL2 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.